Roquin-dependent gene regulation in immune-mediated diseases and future therapies

Int Immunol. 2023 Apr 4;35(4):159-170. doi: 10.1093/intimm/dxac059.

Abstract

The RNA-binding proteins Roquin-1/2 and Regnase-1 exert essential regulation by controlling pro-inflammatory mRNA expression to prevent autoimmune disease. More recently, inhibition of this post-transcriptional gene regulatory program has been demonstrated to enable enhanced anti-tumor responses by tumor antigen-specific CD8+ T cells. In this review, we describe the functions of these RNA-binding proteins and the phenotypes that arise in association with genetic inhibition or inactivation. We discuss how inducible inactivation of the system reprograms CD4+ and CD8+ T cell fates by changing cell metabolism, activation, differentiation or effector/memory decisions. We furthermore outline what we need to know to precisely modulate this system in order to dampen autoimmune reactions or boost the efficacy of adoptively transferred T cells or chimeric antigen receptor (CAR) T cells in cancer immunotherapies.

Keywords: Regnase-1; autoimmunity; autoinflammation; cancer therapy; post-transcriptional gene regulation.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoimmune Diseases* / genetics
  • Autoimmune Diseases* / therapy
  • Cell Differentiation
  • Endoribonucleases / metabolism
  • Gene Expression Regulation*
  • Humans
  • RNA-Binding Proteins / metabolism
  • Ubiquitin-Protein Ligases / metabolism

Substances

  • Endoribonucleases
  • RNA-Binding Proteins
  • Ubiquitin-Protein Ligases